183 related articles for article (PubMed ID: 31300829)
1. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature.
Bailey L; Taylor D
Psychopharmacology (Berl); 2019 Nov; 236(11):3081-3092. PubMed ID: 31300829
[TBL] [Abstract][Full Text] [Related]
2. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE
Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710
[TBL] [Abstract][Full Text] [Related]
3. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
Quraishi S; David A
Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
[TBL] [Abstract][Full Text] [Related]
4. Steady-state serum concentrations after cis (Z)-flupentixol decanoate in viscoleo.
Saikia JK; Jørgensen A
Psychopharmacology (Berl); 1983; 80(4):371-3. PubMed ID: 6414008
[TBL] [Abstract][Full Text] [Related]
5. Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Maayan N; Quraishi SN; David A; Jayaswal A; Eisenbruch M; Rathbone J; Asher R; Adams CE
Cochrane Database Syst Rev; 2015 Feb; 2015(2):CD000307. PubMed ID: 25654768
[TBL] [Abstract][Full Text] [Related]
6. [Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Scherer J; Dobmeier P; Kuhn K; Schmaus W
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S167-9. PubMed ID: 15570542
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients.
Stauning JA; Kirk L; Jøorgensen A
Psychopharmacology (Berl); 1979 Sep; 65(1):69-72. PubMed ID: 116292
[TBL] [Abstract][Full Text] [Related]
9. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Turner M; Eerdekens E; Jacko M; Eerdekens M
Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.
Frey S; Linder R; Juckel G; Stargardt T
Eur J Health Econ; 2014 Mar; 15(2):133-42. PubMed ID: 23420082
[TBL] [Abstract][Full Text] [Related]
11. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate.
Jørgensen A; Andersen J; Bjørndal N; Dencker SJ; Lundin L; Malm U
Psychopharmacology (Berl); 1982; 77(1):58-65. PubMed ID: 6812119
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
Eberhard G; Hellbom E
Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with flupentixol results of a post-marketing surveillance study.
Messer T; Glaser T; Landen H; Schmauss M
J Psychopharmacol; 2009 Sep; 23(7):805-13. PubMed ID: 18562418
[TBL] [Abstract][Full Text] [Related]
15. Flupentixol and flupentixol decanoate, with special reference to their antipsychotic effect.
Gottfries CG
Acta Psychiatr Belg; 1974 Sep; 74(5):507-16. PubMed ID: 4620362
[No Abstract] [Full Text] [Related]
16. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
17. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
18. Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment.
Emsley R; Asmal L; du Plessis S; Chiliza B; Phahladira L; Kilian S
Psychol Med; 2017 Sep; 47(12):2187-2196. PubMed ID: 28347393
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS
JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035
[TBL] [Abstract][Full Text] [Related]
20. Flupenthixol decanoate and injection site abscesses in an obese patient.
Andrade C
Aust N Z J Psychiatry; 2002 Aug; 36(4):561-2. PubMed ID: 12169162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
